​
​

Neurogene Stock (NASDAQ:NGNE)

ForecastRevenueOwnershipFinancialsChart
Neurogene by TradingView

Previous Close

$19.82

52W Range

$12.49 - $74.49

50D Avg

$46.80

200D Avg

$39.05

Market Cap

$223.88M

Avg Vol (3M)

$216.21K

Beta

-

Div Yield

-

NGNE Company Profile

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

91

IPO Date

Mar 07, 2014

Website

NGNE Performance

NGNE Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-55.58M$-56.52M$-50.53M
Net Income$-36.32M$-55.19M$-50.52M
EBITDA$-49.36M$-51.99M$-49.57M
Basic EPS$-2.83$-37.80$-34.60
Diluted EPS$-2.83$-37.80$-34.60

Fiscal year ends in Dec 23 | Currency in USD